Tumor Size is Associated with Adjuvant Chemotherapy Benefit in T1N0M0 Triple-negative Breast Cancer: a Multicenter and Propensity Score Matched Analysis

Overview

Journal Gland Surg

Publisher AME Publishing Company

Specialty Endocrinology

Date 2023 Nov 29

PMID 38021197

Authors

Chenghui Wu

Ou Huang

Jiayi Wu

Kunwei Shen

Xiaosong Chen

Siji Zhu

Affiliations

Soon will be listed here.

Abstract

Background: Triple-negative breast cancer (TNBC) is characterized by aggressive phonotypes and relatively poor outcomes. There are controversies on the effect of adjuvant chemotherapy in small (T1N0M0) TNBCs, especially among T1a-b patients. This study evaluated the survival benefit of adjuvant chemotherapy and influential factors in T1N0M0 TNBC patients.

Methods: All T1N0M0 TNBC patients were identified from the Shanghai Jiao Tong University Breast Cancer Database (SJTU-BCDB) between January 2009 and December 2021. Propensity score matched (PSM) was applied to create a matched cohort. We used Kaplan-Meier analysis and Cox regression models to evaluate the associations of adjuvant chemotherapy with breast cancer-free interval (BCFI) and overall survival (OS). Stratified analysis according to different influential factors was also performed.

Results: In total, 1,113 T1N0M0 TNBC patients (297 T1a, T1b and 816 T1c) were enrolled, including 928 patients with adjuvant chemotherapy and 185 patients without adjuvant chemotherapy. After matching 441 patients by using PSM analysis, 294 patients with chemotherapy and 147 patients without chemotherapy were identified. Patients with or without chemotherapy had similar BCFI (P=0.241) and OS (P=0.509). However, regarding patients with different tumor sizes, adjuvant chemotherapy could significantly improve BCFI in T1c patients (5-year BCFI: 92.1% 79.5%, P=0.035) but not in T1a-b patients (5-year BCFI: 93.6% 94.6%, P=0.546). No significant difference in OS was observed among patients with different tumor sizes. Subgroup analysis found that only tumor size was significantly associated with adjuvant chemotherapy benefit in terms of BCFI (P=0.021) and OS (P=0.040).

Conclusions: The survival benefit of adjuvant chemotherapy was significantly associated with tumor size in T1N0M0 TNBC. Benefit of adjuvant chemotherapy was found in T1c, but not in T1a-b patients. Our findings do not support the routine use of chemotherapy in patients with T1a-bN0 TNBC.

Citing Articles

Prognostic value of adjuvant chemotherapy for hormone receptor-negative T1a and T1bN0M0 breast cancer patients.

Liu Y, Li H, Li J, Wei C, Zeng J, Tian Q Sci Rep. 2025; 15(1):2260.

PMID: 39824952 PMC: 11742062. DOI: 10.1038/s41598-025-85434-z.

Evaluating Treatment Outcomes in Women with Node-Negative T1 Breast Cancers.

Chan P, Ong K, Kuah S, Sim E, Chen J, Goh M Cancers (Basel). 2025; 16(24.

PMID: 39766127 PMC: 11727167. DOI: 10.3390/cancers16244228.

References

Theriault R, Litton J, Mittendorf E, Chen H, Meric-Bernstam F, Chavez-MacGregor M . Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer. 2011; 11(5):325-31. PMC: 4104010. DOI: 10.1016/j.clbc.2011.05.002. View

Bianchini G, De Angelis C, Licata L, Gianni L . Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2021; 19(2):91-113. DOI: 10.1038/s41571-021-00565-2. View

Bleyer A, Welch H . Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2012; 367(21):1998-2005. DOI: 10.1056/NEJMoa1206809. View

Lluch A, Barrios C, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J . Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol. 2019; 38(3):203-213. PMC: 6968797. DOI: 10.1200/JCO.19.00904. View

Won K, Spruck C . Triple‑negative breast cancer therapy: Current and future perspectives (Review). Int J Oncol. 2020; 57(6):1245-1261. PMC: 7646583. DOI: 10.3892/ijo.2020.5135. View

Burstein H, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P . Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019; 30(10):1541-1557. DOI: 10.1093/annonc/mdz235. View

Gradishar W, Moran M, Abraham J, Aft R, Agnese D, Allison K . Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(6):691-722. DOI: 10.6004/jnccn.2022.0030. View

Gorshein E, Klein P, Boolbol S, Shao T . Clinical significance of HER2-positive and triple-negative status in small (≤ 1 cm) node-negative breast cancer. Clin Breast Cancer. 2014; 14(5):309-14. DOI: 10.1016/j.clbc.2014.02.007. View

Loi S, Drubay D, Adams S, Pruneri G, Francis P, Lacroix-Triki M . Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol. 2019; 37(7):559-569. PMC: 7010425. DOI: 10.1200/JCO.18.01010. View

10.

Weigelt B, Peterse J, J van t Veer L . Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005; 5(8):591-602. DOI: 10.1038/nrc1670. View

11.

Ren Y, Hao S, Jin X, Ye F, Gong Y, Jiang Y . Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer. Breast. 2018; 43:97-104. DOI: 10.1016/j.breast.2018.11.011. View

12.

Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner B, Weber K . Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2017; 19(1):40-50. DOI: 10.1016/S1470-2045(17)30904-X. View

13.

Loi S, Michiels S, Adams S, Loibl S, Budczies J, Denkert C . The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Ann Oncol. 2021; 32(10):1236-1244. DOI: 10.1016/j.annonc.2021.07.007. View

14.

Park J, Jonas S, Bataillon G, Criscitiello C, Salgado R, Loi S . Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. Ann Oncol. 2019; 30(12):1941-1949. DOI: 10.1093/annonc/mdz395. View

15.

Gerber B, Loibl S, Eidtmann H, Rezai M, Fasching P, Tesch H . Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol. 2013; 24(12):2978-84. DOI: 10.1093/annonc/mdt361. View

16.

Ho A, Gupta G, King T, Perez C, Patil S, Rogers K . Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy. Cancer. 2012; 118(20):4944-52. DOI: 10.1002/cncr.27480. View

17.

Steenbruggen T, van Werkhoven E, van Ramshorst M, Dezentje V, Kok M, Linn S . Adjuvant chemotherapy in small node-negative triple-negative breast cancer. Eur J Cancer. 2020; 135:66-74. DOI: 10.1016/j.ejca.2020.04.033. View

18.

Thike A, Yong-Zheng Chong L, Cheok P, Li H, Yip G, Bay B . Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. Mod Pathol. 2013; 27(3):352-60. DOI: 10.1038/modpathol.2013.145. View

19.

Bianchini G, Balko J, Mayer I, Sanders M, Gianni L . Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016; 13(11):674-690. PMC: 5461122. DOI: 10.1038/nrclinonc.2016.66. View

20.

Zheng Y, Liu Y, Deng Z, Liu G, Xie N . Determining prognostic factors and optimal surgical intervention for early-onset triple-negative breast cancer. Front Oncol. 2022; 12:910765. PMC: 9650239. DOI: 10.3389/fonc.2022.910765. View